Home

Scott Requadt

CIK 1664852 · Chief Executive Officer · last filed 2025-10-15

Scott Requadt is a Chief Executive Officer who has filed 20 SEC Form 4 insider transactions across 4 companies since 2017. Across all open-market trades the lifetime net is +$239.4K, making them a net buyer over the disclosed history. 4 SEC filings were submitted jointly with Clarus Lifesciences III, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

20

Lifetime Open-Market Net

$239.4K

Filer Profile

Reported Address
101 MAIN STREET, SUITE 1210
CAMBRIDGE, MA 02142
Related Filers
Clarus Lifesciences III, L.P. — 4 joint filings, latest 2018-10-02
Clarus Ventures III GP, L.P. — 4 joint filings, latest 2018-10-02
Clarus Ventures III, LLC — 4 joint filings, latest 2018-10-02
DENNIS HENNER — 4 joint filings, latest 2018-10-02
ROBERT LIPTAK — 4 joint filings, latest 2018-10-02
Nicholas Simon — 4 joint filings, latest 2018-10-02
KURT WHEELER — 4 joint filings, latest 2018-10-02
NICHOLAS GALAKATOS — 2 joint filings, latest 2018-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ESSA Pharma Inc. (EPIX) Delisted Director 42,502 $0.20 $8.6K $0 5 2024-03-28
Tourmaline Bio, Inc. (TALS) Delisted Chief Executive Officer 102,817 $27.20 $2.80M $239.4K 7 2023-07-06
VBI Vaccines Inc/BC (VBIV) Delisted Director 1,250 $0.07 $82 $0 5 2019-02-04
Tectonic Therapeutic, Inc. (AVRO) Delisted Director 246,860 $16.80 $4.15M $0 1 2018-06-25

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-10-15 — Disp (D) −30,002 $0
2024-03-28 ESSA Pharma Inc. (EPIX) Delisted Grant (A) — $0 EDGAR
2024-01-16 ESSA Pharma Inc. (EPIX) Delisted Other (J) −30,002 $0 EDGAR
2023-07-06 Tourmaline Bio, Inc. (TALS) Delisted Tax (F) −11,786 -$36.3K EDGAR
2023-07-05 TRML Notice (144) −11,786 -$36.3K EDGAR
2023-02-03 Tourmaline Bio, Inc. (TALS) Delisted Grant (A) +4 $3 EDGAR
2022-11-01 ESSA Pharma Inc. (EPIX) Delisted Grant (A) — $0 EDGAR
2022-09-13 Tourmaline Bio, Inc. (TALS) Delisted Grant (A) +80,000 $0 EDGAR
2022-08-02 Tourmaline Bio, Inc. (TALS) Delisted Buy (P) +39,382 $167.4K EDGAR
2022-07-28 Tourmaline Bio, Inc. (TALS) Delisted Buy (P) +8,618 $36.6K EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.